Rosuvastatin: A Review of the Pharmacology and Clinical Effectiveness in Cardiovascular Disease

Rosuvastatin is a new generation HMG-CoA reductase inhibitor which exhibits some unique pharmacologic and pharmacokinetic properties. It has low extrahepatic tissue penetration, low potential for CYP3A4 interactions and substantial LDL-C lowering capacity and therefore has distinct advantages. We co...

Descripción completa

Detalles Bibliográficos
Autores principales: Luvai, Ahai, Mbagaya, Wycliffe, Hall, Alistair S., Barth, Julian H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2012
Materias:
Expert Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3303484/
https://www.ncbi.nlm.nih.gov/pubmed/22442638
http://dx.doi.org/10.4137/CMC.S4324

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3303484/
https://www.ncbi.nlm.nih.gov/pubmed/22442638
http://dx.doi.org/10.4137/CMC.S4324

Ejemplares similares